Dr. Reddy's Laboratories (NVO) will launch its off-patent version of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy Ozempic in Canada within the “next few days,” becoming the first to sell a generic ...

Patent expiry across API, formulation, and device IP is expected to catalyze biosimilar competition, expanding access while compressing pricing across pharmaceutical and device value chains.

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

The number of overseas acquisitions by Indian drug companies has been steadily rising and is expected to continue growing as they scale up their ambitions, driven by a desire to move up the value ...

NEW DELHI: A wave of affordable generic versions of Ozempic and Wegovy (semaglutide) has rapidly captured around 20% of the nearly Rs 1,600 crore weight-loss market within days of launch, following ...

The FDA has approved the first generic versions of Farxiga, a drug used to treat Type 2 diabetes and reduce the risk of hospitalization for heart failure. The generic, dapagliflozin, is indicated to ...

The FDA approved the first generics of dapagliflozin (Farxiga) tablets for adults with type 2 diabetes, the agency announced on Tuesday. Generics of the SGLT2 inhibitor are indicated for glycemic ...

March 31 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...